Ninety percent of human diseases are related to abnormal inflammation. WJM team has successfully developed a new monoclonal antibody that can inhibit a key inflammation protein. Animal experiments have accumulated more than ten disease modes, including a variety of solid tumors, fibrosis, degenerativecardiovascular diseases. This antibody is qualified as an orphan drug for the treatment of IPF. New coronary pneumonia has greatly increased the demand for pulmonary fibrosis treatment,has also become an important target for mergersacquisitions of global pharmaceutical companies.

A high-sensitivity quantitative ELISA detection system for the large HBV surface (LHBS) protein was developed. It includes monoclonal antibodies for LHBSchemiluminescent sandwich ELISA method. Clinical tests of the ELISA prodcuts have been performed in CHB cases. The LHBS detection methodsproducts have been filed for US provisional patentwill be submitted for the IVD approval.

The technology optimizes the antigen protein expression system, so that the structural protein Erns of CFSV converts insoluble proteins into soluble proteins during the production process. The breakthrough of this technology allows the antigen protein to be applied to the development of an immune attachment screening platform, as a specialized differential diagnostic reagents can distinguish between virus-infectedvaccinated pigs, which can be applied to the monitoring system of virus transmission rangevaccination